A Response to the Letter to the Editor: Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC.
Ryoko I HigashiyamaTatsuya YoshidaPublished in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (2024)